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Abstract
During antiviral drug discovery, it is critical to distinguish molecules that selectively interrupt viral replication from those
that reduce virus replication by adversely affecting host cell viability. In this report we investigate the selectivity of inhibitors
of the host chaperone proteins cyclophilin A (CypA) and heat-shock protein 90 (HSP90) which have each been reported to
inhibit replication of hepatitis C virus (HCV). By comparing the toxicity of the HSP90 inhibitor, 17-(Allylamino)-17-
demethoxygeldanamycin (17-AAG) to two known cytostatic compounds, colchicine and gemcitabine, we provide evidence
that 17-AAG exerts its antiviral effects indirectly through slowing cell growth. In contrast, a cyclophilin inhibitor, cyclosporin
A (CsA), exhibited selective antiviral activity without slowing cell proliferation. Furthermore, we observed that 17-AAG had
little antiviral effect in a non-dividing cell-culture model of HCV replication, while CsA reduced HCV titer by more than two
orders of magnitude in the same model. The assays we describe here are useful for discriminating selective antivirals from
compounds that indirectly affect virus replication by reducing host cell viability or slowing cell growth.
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Introduction
Intensive efforts are underway to develop new therapies for
hepatitis C virus (HCV). HCV drugs can be broadly classified into
two groups by target: (1) direct acting antivirals (those that inhibit
the virus by directly interacting with viral proteins) or (2) host-
targeted antivirals (drugs that indirectly inhibit the virus by
modulating host protein function). Treatment with ribavirin and
pegylated interferon-a is the current standard of care for chronic
HCV-infection. Pegylated interferon-a is a host-targeted antiviral
that exerts an antiviral effect indirectly through the host immune
response [1]. Multiple direct-acting antivirals have been shown to
reduce viral load in patients, but rapid emergence of drug
resistance is a common outcome after monotherapy [2]. Host-
factor inhibitors generally offer superior barriers to resistance as
compared to direct acting antivirals [3,4], with a few notable
exceptions [5]. Targeting a host factor; however, potentially
introduces a higher risk of side-effects, depending on the function
and nature of the host protein being targeted. Assessing the risks
and benefits of unique antiviral targets remains a challenge in
antiviral drug discovery.
Inhibitors of two host factor targets, Cyclophilin A (CypA) and
heat-shock protein 90 (HSP90), have shown selective antiviral
activity with a high barrier to resistance. The cyclosporin A-analog
Debio-025, which inhibits CypA, reduced viral load in combina-
tion with pegylyated interferon-a and ribavirin, without the
emergence of viral resistance and has been generally well-tolerated
[4]. 17-(Allylamino)-17-demethoxygeldanamycin, (17-AAG), an
HSP90 inhibitor, showed potent pre-clinical efficacy against a
number of viral targets including hepatitis C [6,7], ebola [8],
hepatitis B [9,10],and influenza [11]. Drug-resistance is suppressed
by HSP90 inhibitors in polio-infected mice [3]. Further, clinical
trials of 17-AAG demonstrated safety and tolerability [12,13].
Together, these data suggest that HCV inhibitors targeting CypA
or HSP90 have the potential to be well tolerated with a high
barrier to resistance.
CypA and HSP90 are both chaperone proteins thought to aid in
HCV replication. CypA is an 18 kDa protein that exhibits
peptide-prolyl isomerase activity against a broad range of
substrates [14]. HSP90 is an ATP-dependent chaperone protein
[15]. Both proteins are highly abundant and play an important
role in host protein folding. Both CypA and HSP90 have been
shown to specifically interact with the HCV NS5A protein [16,17].
Thus, disruption of the interaction with NS5A may be responsible
for the observed antiviral activity of CsA or 17-AAG, rather than
some non-specific interference with cellular processes.
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toxicity is critical in antiviral drug discovery. The cell-based assays
typically used in pre-clinical antiviral research generally rely on
rapidly-dividing immortalized cells as hosts for viral replication
[18]. In contrast, most viruses infect non-dividing cells in vivo.
Molecules that slow immortalized-cell growth may cause an
apparent (but non-specific) reduction in viral replication [19]. To
further complicate interpretation of toxicity measurements in
cultured cell lines, various end-point assays (e.g., tetrazolium salts,
Calcein AM, and luciferase-coupled assays) are often employed
interchangeably despite measuring distinct surrogate markers for
cell health or viability (mitochondrial reduction potential,
intracellular esterase activity, and intracellular ATP concentra-
tions, respectively). This creates the possibility that a putative
antiviral molecule may exert its effect indirectly by inducing a
partial or unobserved cellular toxicity (i.e., a cytostatic effect). The
magnitude and potency of any effect on cell growth, health,
viability, and toxicity must be assessed to distinguish truly selective
antiviral activity.
Here we provide in vitro evidence that CsA (but not 17-AAG) is a
selective inhibitor of HCV replication. We compared the antiviral
efficacy and toxicity of the HSP90 inhibitor 17-AAG to the CypA
inhibitor CsA. Neither 17-AAG nor CsA were cytotoxic (as
assessed by intracellular esterase levels) at their effective antiviral
concentrations. However, when cellular growth was measured
directly (by time-lapse microscopy), we observed that 17-AAG (but
not CsA) slowed cellular replication at the same concentrations
required to inhibit HCV replication. This suggested that 17-AAG
might inhibit HCV replication by non-specifically slowing cellular
growth. To further investigate this, we tested both compounds in
antiviral assays with either dividing or non-dividing cells. CsA
maintained antiviral activity in both rapidly-dividing and non-
dividing cells, but 17-AAG did not exhibit antiviral activity in non-
dividing cells. We show that 17-AAG inhibits HCV replication
through slowing cellular replication, while CsA has a specific
antiviral effect. Furthermore, our work describes specific assays to
distinguish between compounds that selectively inhibit viral
replication from those which indirectly inhibit viral replication
by slowing cellular growth.
Results
17-AAG potently inhibits HCV replication, but also
partially reduces intracellular esterase levels
We compared the anti-HCV activity and toxicity of CsA and
17-AAG to a panel of selective antiviral (HCV-796), cytostatic
(gemcitabine and colchicine), and highly toxic (Puromycin)
compounds. Using a stable cell line replicating a luciferase-
encoding HCV replicon, we measured viral replication levels
(Renilla luciferase) across a range of drug concentrations (2 nM to
44.4 mM) three days post drug addition. In parallel, we measured
intracellular esterase activity as a surrogate for cell viability using
the Calcein AM reagent.
Antiviral replicon assays yielded standard dose-response curves
ranging from 0 to 100% inhibition with EC50 values between 9
and 290 nM for all compounds. In contrast, the intracellular
esterase activity assays yielded either no dose response (no toxicity),
a full dose response (0 to 100% cell viability), or a partial dose
response (e.g. cell viability was reduced, but reached a plateau
between 0 and 50%). The HCV NS5B inhibitor HCV-796, a
potent direct-acting antiviral [20], showed full antiviral activity
without any observable cytotoxicity (Fig. 1A). The ribosome
inhibitor puromycin (Fig. 1B), a known toxin [21], reduced
intracellular esterase activity from 100% to 0% of the untreated
control and fit a sigmoidal dose-response relationship. There was
little difference between the apparent antiviral activity and
cytotoxicity of puromycin in this assay (EC50 within 4-fold of
CC50). The Cyclophilin inhibitor CsA [22] did exhibit cellular
toxicity, but the concentrations required for the toxic effect were
much higher (.20-fold) than the concentrations required for the
antiviral effect (Fig. 1C). The microtubule inhibitor colchicine [23]
(Fig. 1D) and the anti-metabolite gemcitabine [19](Fig. 1E), known
cytostatic molecules, each demonstrated a full antiviral response
with EC50 values of 9 and 12 nM, respectively (Table 1). However
these compounds only partially reduced intracellular esterase
activity at the majority of concentrations tested. The HSP90
inhibitor 17-AAG (Fig. 1F) demonstrated a full antiviral dose
response with an EC50 of 12 nM (Table 1), but it had a complex,
and biphasic effect on intracellular esterase activity. A partial
reduction in intracellular esterase activity, similar to the colchicine
and gemcitabine was observed at concentrations between 20 and
5,000 nM (Fig. 1D and E). While a CC50 value could be calculated
in all cases (Table 1), the non-standard dose-response relationships
observed may obscure the interpretation of these values.
Colchicine, gemcitabine, and 17-AAG all interrupted viral
replication with EC50 values between 9–12 nM (Table 1), but it
appeared that all three compounds were also altering cellular
viability at concentrations between 20 and 5,000 nM.
17-AAG potently reduces intracellular ATP concentration
To better assess the toxicity of the host-factor inhibitors CsA
and 17-AAG, we employed an alternative assay for cellular
viability that measured intracellular ATP levels (CellTiter-Glo) in
the same replicon cell lines. For HCV-796 (Fig. 2A), puromycin
(Fig. 2B), and CsA (Fig. 2C), the intracellular ATP toxicity assay
yielded results nearly identical to the Calcein assay. In contrast to
the partial effect on intracellular esterase activity observed using
the Calcein assay, colchicine reduced intracellular ATP signal to
,7% of the untreated controls (Fig. 2D). Gemcitabine (Fig. 2E)
and 17-AAG (Fig. 2F) also appeared to have potent toxicity based
on the intracellular ATP assay, although the highest doses still did
not fully reduce the signal to 0% of the untreated controls. Like the
known-cytostatic gemcitabine, 17-AAG partially reduced viability
at concentrations close to the EC50 value in both surrogate assays
for cellular viability. In contrast, CsA, exhibited antiviral activity at
concentrations 20- to 50-fold below those required for toxicity
(Table 1).
17-AAG potently reduces cell number
Because toxicity assays using different surrogates of cell number
provided varying results, we next measured cell number directly
by determining the number of Hoechst-stained nuclei after three
days of incubation with each drug. Colchicine was excluded from
this analysis because its effect on microtubules distorts cellular
morphology and prevents accurate quantification of nuclei. By
directly counting cells, we observed dose responses that were
generally similar to those observed with the intracellular ATP
assay (Fig. 3). Notably, the magnitude of the effect on cell number
at the highest concentrations of compound tested was similar to
the magnitude of the effect on intracellular ATP levels. HCV-796
was non-toxic at all concentrations tested. Puromycin and very
high concentrations of CsA eliminated all cells in the field.
Gemcitabine and 17-AAG reduced the number of cells at high
concentrations but did not eliminate all cells. This observation is
consistent with a cytostatic, but not cytotoxic, effect. The CC50
values calculated from this experiment (Table 1) were close to, but
generally lower than, the CC50’s calculated from the intracellular
ATP assay data.
17-AAG Inhibits HCV by Slowing Cellular Growth
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number and morphology, images of cells treated with 1 mM
compound were visually inspected (Fig. 4). 1 mM puromycin
eliminated all cells in the course of the three-day assay (Fig. 4B).
1 mM 17-AAG (Fig. 4F) or gemcitabine (Fig. 4E) reduced the
number of cells per image to ,22% of the controls. Neither 1 mM
CsA (Fig. 4C) nor HCV-796 (Fig. 4A) altered the number of cells
per image when compared to the no-drug control (Fig. 4D). In
agreement with the intracellular ATP assay data, these data
suggested that the antiviral effect of puromycin, gemcitabine, and
17-AAG was a consequence of adverse effects on cell health or
proliferation. In contrast, CsA and HCV-796 display antiviral
activity at concentrations that do not alter cell number.
17-AAG slows cell growth at concentrations similar to its
effective antiviral concentration
Two possible mechanisms could cause the reduction in both
intracellular ATP levels and the number of cells observed at 17-
AAG concentrations close to the EC50: either reduced cellular
proliferation rate or delayed toxicity, in which cells proliferate
normally for 1–2 days, but subsequently undergo rapid cell death
on days 2–3. To distinguish between these two mechanisms, we
directly measured cellular confluence (the percent of the culture
well occupied by cells, % confluence) every four hours and
quantified cellular replication rates. 1 mM 17-AAG slowed the
kinetics of cellular proliferation significantly compared to 1 mM
HCV-796 (Fig. 5A). 1 mM CsA, in contrast, did not impair cellular
Figure 1. Effect of 17-AAG and CsA on HCV replication and viability determined by intracellular esterase activity. Antiviral activity
(measured using the Renilla luciferase encoded by the HCV replicon; gray) and cell viability (measuring through the cleavage of calcein-AM by
intracellular esterases; black) were assessed as a function of dose in a three day assay for the following molecules: (A) the HCV polymerase inhibitor
HCV-796, (B) the ribosomal inhibitor puromycin, (C) the cyclophilin inhibitor CsA, (D) the microtubule inhibitor colchicine, (E) the anti-metabolite
gemcitabine, and (F) the HSP90 inhibitor 17-AAG.
doi:10.1371/journal.pone.0030286.g001
Table 1.
Compound Target EC50 (nM) CC50 (nM)
Calcein Intracellular ATP Cell #
HCV-796 HCV NS5B 15 .44,444 .44,444 .44,444
Cyclosporine A Cyclophilin A 259 13,830 11,930 10,210
17-AAG HSP90 12 21,040* 38 5
Gemcitabine Ribonucleotide reductase 12 .44,444 6 4
Colchicine Microtubules 9 .44,444* 16 ND**
Puromycin Ribosome 290 1,070 516 52
*Non-standard dose-response curve.
**Altered cell morphology interferes with accurate cell number determination.
doi:10.1371/journal.pone.0030286.t001
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elimination of cells observed with puromycin (Fig. 5A). Consistent
with Figure 4, inspection of the images confirmed a decreased
number of cells per field (and not an aberration in cell size or
spreading) for the 17-AAG-treated cells. These data demonstrate
that 1 mM 17-AAG reduced the cellular growth rate.
We next determined if 17-AAG slows cell growth at the same
concentration at which it inhibits HCV replication. We quantified
growth rate by assessing the change in % confluence between days
1 and 2 (% confluence/day) and measured the effect of growth
rate as a function of dose. At concentrations as low as 22 nM, 17-
AAG caused a significant decrease in growth rate (18.0+/21.1%
confluence/day) (Fig. 5B) as compared to the control (24.3+/
22.1% confluence/day) (Fig. 5B). This 22 nM minimum
inhibitory concentration (MIC) for 17-AAG is similar to its
effective concentration for inhibiting HCV replication
(EC50=12 nM). Like 17-AAG, the known toxin puromycin had
an MIC of 205 nM (Fig. 5B) which is also similar to its effective
concentration (EC50=290 nM). HCV-796 did not significantly
impair cell proliferation at any concentration tested. For CsA, the
MIC was 5.6 mM (Fig. 5B) which was more than 20-fold above the
EC50. Inhibition of CypA or HSP90; therefore, can cause very
distinct effects on cellular proliferation.
Because measurements of cellular confluence do not necessarily
account for cell viability, we used trypan-blue exclusion to
determine the number of viable cells. Cells treated were
trypsinized and quantified at multiple timepoints post drug
addition (Fig. 5C). 1 mM 17-AAG or puromcyin reduced the
number of viable cells equally effectively. Neither CsA nor HCV-
796 treatment affected cell viability. In agreement with the
intracellular ATP concentration assay data, these results suggest
that 17-AAG and puromycin adversely affect cell viability at a
concentration of 1 mM.
17-AAG does not inhibit HCV replication in non-dividing
cells
Because 17-AAG slows cellular proliferation at concentrations
similar to its effective concentration for inhibiting HCV replica-
tion, we next assessed whether it inhibited HCV replication in
non-dividing cells. We first established a non-dividing monolayer
of Lunet-CD81 cells [24] and then infected that monolayer with
cell-culture adapted virus capable of spreading and infecting all of
the cells in a culture [25]. After the cell cultures were ,100%
infected, we added compounds at a concentration 10-fold above
the EC50 (Fig. S1) and measured the extracellular viral titer
produced at several time points over a 7-day incubation (see
Materials and Methods). When the fully-infected non-dividing
cultures were treated with DMSO alone, the extracellular viral
titer remained relatively constant at between 10
5 and 10
6
TCID50/ml over time (Fig. 6A). However, treatment with 10-
fold excess (i.e. 106EC50) CsA or HCV protease inhibitor BILN-
2061 resulted in a sustained 2-log suppression of infectious HCV
titer over the 7-day time course (Fig. 6A). In contrast, 17-AAG
treatment resulted in a much more modest (0.6 log on day 2) and
transient (0.3 log on Day 7) reduction of infectious HCV titer
(Fig. 6A). The reduction in HCV titer caused by 17-AAG, may at
Figure 2. Effect of 17-AAG and CsA on cellular viability determined by measuring intracellular ATP concentration. Cell viability
(measured by determining intracellular ATP levels) was assessed as a function of dose in a three day assay for the following molecules: (A) the HCV
polymerase inhibitor HCV-796, (B) the ribosomal inhibitor puromycin, (C) the cyclophilin inhibitor CsA, (D) the microtubule inhibitor colchicine, (E) the
anti-metabolite gemcitabine, and (F) the HSP90 inhibitor 17-AAG.
doi:10.1371/journal.pone.0030286.g002
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dividing monolayers at the concentrations used. 17-AAG treat-
ment reduced the number of cells to 74% of the DMSO-treated
control, but neither CsA nor BILN 2061-treatment decreased the
number of cells in the non-dividing monolayers (data not shown).
As a comparative control, we performed the same compound-
treatment using fully-infected cultures that were still dividing (see
Materials and Methods). 17-AAG treatment reduced the level of
infectious HCV in dividing cells by roughly 2 logs after 24 hours of
treatment (Fig. 6B). The inhibitory effect of 17-AAG was
diminished only as the cell cultures reached confluence (days 3
and 4 post-compound addition) (Fig. 6B). These results suggest
that HCV replication inhibition by 17-AAG is caused by
suppression of cell proliferation. In contrast, CsA and BILN-
2061 inhibited viral titers in both dividing and non-dividing cells.
Discussion
Targeting host factors essential for viral replication has the
potential to identify new antiviral molecules with high barriers to
drug resistance. Toward this end, many groups have screened for
host factors essential for viral replication [26–28]. However, this
strategy requires thorough assessment of cellular toxicity to ensure
that an observed antiviral activity is not confounded by inhibition
of cellular proliferation. From the data reported here, we
concluded that effects on cell growth correlate with the antiviral
activity observed for molecules like gemcitabine and 17-AAG. We
also found that certain cell-based assays using biochemical
surrogates for cell number may under-represent the effects of
these molecules. However, direct measurements of cell number
and cell growth clearly distinguished selective antivirals, like CsA,
from molecules that slow cellular proliferation.
The term ‘‘toxicity’’ is broadly applied to adverse effects on
cellular viability, and our observations underscore the complexity
of accurately measuring toxicity. Compounds such as puromycin
Figure 3. Effect of 17-AAG and CsA on cellular viability determined by cell count. Cell viability (measured by direct microscopic
quantification of Hoechst-stained nuclei) was assessed as a function of dose in a three day assay for the following molecules: (A) the HCV polymerase
inhibitor HCV-796, (B) the ribosomal inhibitor puromycin, (C) the cyclophilin inhibitor CsA, (D) the microtubule inhibitor colchicine, (E) the anti-
metabolite gemcitabine, and (F) the HSP90 inhibitor 17-AAG. Colchicine dramatically altered cellular morphology, preventing an accurate cell count.
doi:10.1371/journal.pone.0030286.g003
Figure 4. Visual assessment of replicon cell number and
morphology after 1 mM compound treatment. Hoechst-stained
nuclei were visualized after treatment for three days with the following
molecules: (A) the HCV polymerase inhibitor HCV-796, (B) the ribosomal
inhibitor puromycin, (C) the cyclophilin inhibitor CsA, (D) the
microtubule inhibitor colchicine, (E) the anti-metabolite gemcitabine,
and (F) the HSP90 inhibitor 17-AAG.
doi:10.1371/journal.pone.0030286.g004
17-AAG Inhibits HCV by Slowing Cellular Growth
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The toxicity of 17-AAG, in contrast, is distinct both in mechanism
and cellular phenotype. While puromycin blocks protein synthesis
and results in rapid cellular apoptosis, 17-AAG inhibits HSP90
and reduces cellular viability without inducing rapid apoptosis.
Phenotypically, the magnitude of 17-AAG toxicity was compara-
ble to puromycin in the intracellular ATP and trypan-blue
exclusion assays. The intracellular esterase activity assay, in
contrast, was not as sensitive a measure of 17-AAG toxicity.
Perhaps intracellular esterases are not affected, or may even
accumulate, as 17-AAG slows cell growth. Direct measurements of
cellular confluence suggested that 17-AAG was reducing the
overall rate of cell growth. This indicates that 17-AAG’s effects are
neither immediate (see 20–30 hour timepoints in Figure 5) nor
lytic (Figure 4). Because viral replication may be inhibited by
subtle changes in cellular growth and viability, it is essential to fully
characterize the ‘‘toxicity’’ of a small-molecule inhibitor before
concluding its antiviral activity is truly selective.
Toxicity assessments at single time points are insufficient to
characterize a compound’s effect on cellular growth rate. Kinetic
measurements of cellular proliferation were essential to distinguish
delayed toxicity (in which cells grow at normal rates for 2 days
then begin to lyse between days 2 and 3) from an alteration of
cellular growth rates for 17-AAG. These observations emphasize
the value of a comprehensive assessment of cell viability and
proliferation in antiviral drug discovery.
A potential limitation of many in vitro systems used to assess
antiviral potency, such as the HCV replicon cell line described in
this report, is that they rely on rapidly-dividing immortalized cells
as viral hosts. When evaluating the antiviral potential of host
factors, this creates two distinct problems. First, alterations in
cellular growth rates may be responsible for the perceived antiviral
effects (as we observed for puromycin and 17-AAG). For the HCV
replicon, this is due to the dependence on cellular division. Shortly
after the discovery of the HCV replicon, cellular confluence was
observed to significantly reduce replicon copy number [18,29].
Second, the intracellular environment in immortalized cells is
fundamentally different than that in the primary cells that HCV
infects in vivo. For example, HSP90 is known to reside in complexes
with co-chaperones that are distinct for primary or immortalized
cells [30].
While 17-AAG did not selectively inhibit HCV in our in vitro
assays, the activity observed for other viruses may be more
promising. The mechanisms by which HSP90 promotes viral
replication seem to be distinct between viruses [3,7,8,11,16]. Some
mechanisms may be independent from the effect on cellular
growth rate responsible for the anti-HCV activity. In the case of
poliovirus, HSP90 inhibition limits the number of competent
viruses produced from primary cells and specifically interferes with
capsid maturation [3]. Underscoring the differences in suscepti-
bility between viruses, HSP90 inhibitor monotherapy reduced
viral load of poliovirus-infected mice [3] but not HCV-infected
Figure 5. 17-AAG slows cellular growth at its effective antiviral concentration. (A) Cellular growth was determined by measuring the
percent confluence (by microscopic quantification) every 4 hours. HCV-796 (blue diamonds), CsA (pink squares), puromycin (black triangles), 17-AAG
(green triangles). (B) Growth rate (% confluence per day) as a function of compound dose. HCV-796 (blue diamonds), CsA (pink squares), puromycin
(black triangles), 17-AAG (green triangles). (C) Trypan-blue exclusion was used to determine the number of viable cells each day post drug addition.
HCV-796 (blue diamonds), CsA (pink squares), puromycin (black triangles), 17-AAG (green triangles), or an equivalent volume of DMSO (grey circles).
doi:10.1371/journal.pone.0030286.g005
Figure 6. 17-AAG reduces HCV titer by slowing cellular growth. (A) Non-dividing HCV-infected cultures were treated with 106EC50 for each
compound. Subsequently, extracellular HCV titer was quantified at various times in the presence of DMSO (circles), 0.35 mM HSP90 inhibitor 17-AAG
(triangles), 1.30 mM cyclosporin inhibitor CsA (squares), or 1.40 mM HCV protease inhibitor BILN-2061 (diamonds). The DMSO data were fit to a linear
equation. The CsA and BILN-2061 data were fit to second-order exponential equations. The 17-AAG data could not be fit to first or second order
exponential equations. (B) Dividing HCV-infected cultures were treated with 106EC50 compound. Subsequently, extracellular HCV titer was quantified
at various times in the presence of DMSO (circles), 0.35 mM HSP90 inhibitor 17-AAG (triangles), 1.30 mM cyclophilin inhibitor CsA (squares), or 1.40 mM
HCV protease inhibitor BILN-2061 (diamonds). The DMSO data were fit to a linear equation. The CsA and BILN-2061 data were fit to second-order
exponential equations. The 17-AAG data could not be fit to first or second order exponential equations.
doi:10.1371/journal.pone.0030286.g006
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of viral infection is limited (i.e., influenza or rhinovirus), mild
effects on host cell proliferation may be tolerated. However, in
standard HCV replicon cells the apparent antiviral activity of 17-
AAG is dependent on its ability to slow the cellular replication rate
whereas the antiviral activity of CsA was not. Thus, for HCV
therapy CypA appears to be a more promising target than HSP90.
Materials and Methods
Cell Culture
51C-1a-TdTomato [32], 51C-H77-Rluc [33], and Lunet-CD81
[25] cell lines were propagated in Dulbecco’s Modified Eagle
Medium (D-MEM) with GlutaMAX
TM-I (Invitrogen, Carlsbad,
CA) supplemented with 10% FBS (HyClone, Logan, UT), 1 unit/
ml Penicillin (Invitrogen), 1 mg/ml Streptomycin (Invitrogen), and
0.1 mM non-essential amino acids (Invitrogen). Replicon cell lines
were selected and maintained in 0.5 mg/ml G-418 (Invitrogen).
Antiviral compounds
BILN-2061 was purchased from Acme Bioscience (Belmont,
CA). HCV-796 was synthesized by Curragh Chemistries (Cleve-
land, OH). 17-AAG was purchased from A. G. Scientific (San
Diego, CA). Cyclosporin A was purchased from Alexis Biochem-
icals (San Diego, CA). Colchicine was purchased from Micro-
Source (Gaylordsville, CT). Gemcitabine was purchased from
Toronoto Research Chemicals (North York, Ontario, Canada).
Puromycin was purchased from Sigma Aldrich (St. Louis, MO).
Antiviral assays
Renilla luciferase replicon cell assays were performed as
previously described [33]. Calcein AM (Anaspec, Fremont, CA)
and CellTiter-Glo (Promega, Madison, WI) readouts were
performed as instructed by the manufacturer.
For direct assessment of cell number, genotype 1a replicon cells
were seeded in 384 well plates at 1500 cells/well. Compounds
were added as previously described [33]. Cells were fixed in 1%
paraformaldehyde (Electron Microscopy Sciences) and 25 mg/ml
Hoechst 33342 (Invitrogen) in PBS for 30 minutes at room
temperature. The fixed cells were washed twice with PBS, and
images of each well were acquired with the ImageXpress Micro
(Molecular Devices, Sunnyvale, CA). Nuclei were quantified with
the cell scoring application in MetaXpress (Molecular Devices,
Sunnyvale, CA).
To assess cellular growth, 96 well plates ImageLock plates
(Essen Instruments, Ann Arbor, MI) were seeded at a density of
5610
3 cells/well in culture medium without G418. Percent
confluence was quantified using bright phase images (at 106
magnification) acquired of each well every four hours in an
IncuCyte (Essen Instuments, Ann Arbor, MI). Alternatively,
7.5610
4 cells/well were plated in 6 well plates. Each day post
drug addition, cells were dislodged from the tissue culture plate
using 350 mL trypsin-EDTA and then quenched with 150 mL fetal
bovine serum. The number of cells that exclude trypan-blue was
determined using the Vi-Cell (Beckman Coulter, Fullerton, CA) in
triplicate.
To assess the antiviral potency of compounds in rapidly-dividing
virus-infected cells. we adapted a method from a previously
described assay [34]. Briefly, 1500 cells per well were plated in 384
well-plates. Infection with the HCVcc Min3 virus (core K78E,
NS2 W879R, and NS4B K1761N) [25] was followed by addition
of compound as described [33]. After three days, intracellular
NS3-4A protease activity was assessed [34]. Luciferase, Calcein,
CellTiter-Glo, and NS3-4A levels were expressed as a percent of
the no-drug control.
HCV-infected non-dividing cultures
HCV-infected non-dividing cultures were established by
methods adapted from Sainz and Chisari [24]. Briefly, Lunet-
CD81 cells [25] were seeded in 12-well plates at a density of
50,000 cells/well. The plates were incubated over-night at 37uC
and subsequently DMSO was added to 1% final concentration.
Cells were allowed to grow to confluence over three days.
Infectious HCV (2a) with three adaptive mutations (the Min3
virus) (core K78E, NS2 W879R, and NS4B K1761N) [25] was
then added to each well at an MOI of five. Infection was permitted
to spread for seven days until the cultures were ,100% infected
(by NS5A immunofluorescence). Subsequently, compounds of
interest were added at 106EC50 concentration. 200 ml aliquots of
the extracellular medium were saved daily, stored at 280uC, and
subsequently used for infectious viral titering. After three days, the
compound-medium was refreshed and time points were collected
for seven days. Viral titers as a percentage of the DMSO-treated
control were measured through diluting the extracellular medium
40-fold and using it to infect naı ¨ve Lunet-CD81 cells. After
72 hours of incubation, intracellular HCV replication was
measured by following NS3-4A protease cleavage of a europi-
um-labeled peptide [35].
As a comparative control, fully-infected, growing cell cultures
were prepared as well. Briefly, cells were plated at 25,000 cells/
well on 12-well plates. After the cells adhered to the plate (four
hours post-seeding), they were infected at an MOI of five using
adapted HCV (2a) (see above). The HCV infection was permitted
to spread until the cultures were fully infected (three days post-
infection). Subsequently, compounds were added and extracellular
medium was removed each day and analyzed as described above.
Supporting Information
Figure S1 CsA and 17-AAG maintain potency, similar to
rapidly-dividing replicon cells, in rapidly-dividing virus-
infected cells. The normalized amount of virus, as measured by
enzymatic activity of the NS3-4A protease, was determined as a
function of dose. (A) CsA EC50 was 130 nM (259 nM against the
replicon), and (B) 17-AAG EC50 was 35 nM (12.1 nM against the
replicon). (C) As a control, the protease inhibitor BILN-2061
exhibited an EC50 of 140 nM.
(TIF)
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